<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01675297</url>
  </required_header>
  <id_info>
    <org_study_id>HL_RSNP_401</org_study_id>
    <nct_id>NCT01675297</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis</brief_title>
  <official_title>For 12months, the Multi Center, Randomized, Open-label, Active Controlled Comparative Clinical Study to Assess the Efficacy and the Safety of Risedronate, Cholecalciferol Combination Tablet in Patients With Osteoporosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanlim Pharm. Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanlim Pharm. Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of Risedronate,
      cholecalciferol combination tablet in patients with Osteoporosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the efficacy and the safety of Risedronate with and
      without cholecalciferol on vitamin D status, Bone Mineral Density (BMD) and bone markers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 4, 2011</start_date>
  <completion_date type="Actual">April 15, 2014</completion_date>
  <primary_completion_date type="Actual">December 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Change of Bone Mineral Density (BMD) Value</measure>
    <time_frame>baseline and 12 months</time_frame>
    <description>Higher Bone Mineral Density(BMD) value mean a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Change of 25OHD(25-hydroxyvitamin D)</measure>
    <time_frame>baseline, 6months, 12months</time_frame>
    <description>range of 25OHD: 4.80~52.80 Higher 25OHD scores mean a better outcome.
If there is missing data, LOCF(Last Observation Carried Forward) was applied and analyzed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTH(Parathyroid Hormone Value)</measure>
    <time_frame>baseline, 6months, 12months</time_frame>
    <description>range of PTH: 13~54 Higher PTH scores mean a worse outcome.
If there is missing data, LOCF(Last Observation Carried Forward) was applied and analyzed.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1053</enrollment>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Risendronate/Cholecalciferol combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Risedronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Sedron tablet: one tablet once a week for 12months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate/Cholecalciferol combination</intervention_name>
    <description>Risendronate/Cholecalciferol combination once a week</description>
    <arm_group_label>Risendronate/Cholecalciferol combination</arm_group_label>
    <other_name>RisenexPlus tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risedronate</intervention_name>
    <description>Risedronate once a week</description>
    <arm_group_label>Risedronate</arm_group_label>
    <other_name>Sedron 35mg tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male osteoporosis patients over 19 years of age

          2. Female osteoporosis patients with menopause

               -  Definition of osteoporosis

                    -  They had a BMD T-score -2.5 or less at mean Lumbar spine(L1-L4), Femoral
                       neck or total. Or evidence of at least one vertebral fracture

               -  Definition of menopause(can be one of three condition)

                    -  For 12months spontaneous amenorrhea

                    -  For 6months spontaneous amenorrhea with serum FSH(Follicle stimulating
                       hormone) is 40mlU/mL and over

                    -  6weeks after bilateral ovariectomy whether hysterectomy or not.

        Exclusion Criteria:

          1. Patients with esophagus disorder (i.e:esophagostenosis)

          2. Patients administered with osteoporosis therapy(except calcium, Vit.D
             medication)within the previous 3 Months

          3. Patients with serum calcium concentrations 8.0mg under

          4. Patients with severe nephropathy (CCr 30mL/min less)

          5. Patients with unable to sit upright or stand for 30minutes
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hyoung-Moo Park, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chung-Ang University Hosptial, Chung-Ang University College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chung-ang university hospital</name>
      <address>
        <city>Seoul</city>
        <zip>156-755</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>August 27, 2012</study_first_submitted>
  <study_first_submitted_qc>August 28, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2012</study_first_posted>
  <results_first_submitted>August 15, 2018</results_first_submitted>
  <results_first_submitted_qc>June 23, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">August 5, 2019</results_first_posted>
  <last_update_submitted>June 23, 2019</last_update_submitted>
  <last_update_submitted_qc>June 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Risedronate, cholecalciferol, BMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Risedronic Acid</mesh_term>
    <mesh_term>Etidronic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>medical clinic</recruitment_details>
      <pre_assignment_details>wash out 7~14days</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Risendronate/Cholecalciferol Combination</title>
          <description>Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months.
Risedronate/Cholecalciferol combination: once a week</description>
        </group>
        <group group_id="P2">
          <title>Risedronate</title>
          <description>Active comparator: Administer Risendronate one tablet once a week for 12months.
Risedronate: once a week</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="806"/>
                <participants group_id="P2" count="247"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="642"/>
                <participants group_id="P2" count="199"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="164"/>
                <participants group_id="P2" count="48"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Risendronate/Cholecalciferol Combination</title>
          <description>Risendronate/Cholecalciferol combination Risenex Plus tablet: one tablet once a week for 12months
Risedronate/Cholecalciferol combination: Risendronate/Cholecalciferol combination once a week</description>
        </group>
        <group group_id="B2">
          <title>Risedronate</title>
          <description>Sedron tablet: one tablet once a week for 12months
Risedronate: Risedronate once a week</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="806"/>
            <count group_id="B2" value="247"/>
            <count group_id="B3" value="1053"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65.77" spread="7.87"/>
                    <measurement group_id="B2" value="65.51" spread="8.59"/>
                    <measurement group_id="B3" value="65.71" spread="8.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="754"/>
                    <measurement group_id="B2" value="236"/>
                    <measurement group_id="B3" value="990"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.40" spread="3.32"/>
                    <measurement group_id="B2" value="23.00" spread="3.00"/>
                    <measurement group_id="B3" value="23.31" spread="3.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Osteoporosis disease period</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.90" spread="37.49"/>
                    <measurement group_id="B2" value="27.07" spread="40.44"/>
                    <measurement group_id="B3" value="24.65" spread="38.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Change of Bone Mineral Density (BMD) Value</title>
        <description>Higher Bone Mineral Density(BMD) value mean a better outcome.</description>
        <time_frame>baseline and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risendronate/Cholecalciferol Combination</title>
            <description>Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months.
Risedronate/Cholecalciferol combination: once a week</description>
          </group>
          <group group_id="O2">
            <title>Risedronate</title>
            <description>Active comparator: Administer Risendronate one tablet once a week for 12months.
Risedronate: once a week</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of Bone Mineral Density (BMD) Value</title>
          <description>Higher Bone Mineral Density(BMD) value mean a better outcome.</description>
          <units>g/cm^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" spread="0.11"/>
                    <measurement group_id="O2" value="0.77" spread="0.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.81" spread="0.12"/>
                    <measurement group_id="O2" value="0.80" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>change(12months-baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04" spread="0.05"/>
                    <measurement group_id="O2" value="0.03" spread="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change of 25OHD(25-hydroxyvitamin D)</title>
        <description>range of 25OHD: 4.80~52.80 Higher 25OHD scores mean a better outcome.
If there is missing data, LOCF(Last Observation Carried Forward) was applied and analyzed.</description>
        <time_frame>baseline, 6months, 12months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risendronate/Cholecalciferol Combination</title>
            <description>Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months.
Risedronate/Cholecalciferol combination: once a week</description>
          </group>
          <group group_id="O2">
            <title>Risedronate</title>
            <description>Active comparator: Administer Risendronate one tablet once a week for 12months.
Risedronate: once a week</description>
          </group>
        </group_list>
        <measure>
          <title>The Change of 25OHD(25-hydroxyvitamin D)</title>
          <description>range of 25OHD: 4.80~52.80 Higher 25OHD scores mean a better outcome.
If there is missing data, LOCF(Last Observation Carried Forward) was applied and analyzed.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>25OHD(baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.23" spread="11.59"/>
                    <measurement group_id="O2" value="17.83" spread="10.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25OHD(6months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.93" spread="11.16"/>
                    <measurement group_id="O2" value="19.47" spread="12.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25OHD(12months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.57" spread="11.89"/>
                    <measurement group_id="O2" value="18.35" spread="11.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25OHD change(6months-baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.74" spread="11.53"/>
                    <measurement group_id="O2" value="1.68" spread="9.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25OHD change(12months-baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.33" spread="13.33"/>
                    <measurement group_id="O2" value="0.53" spread="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PTH(Parathyroid Hormone Value)</title>
        <description>range of PTH: 13~54 Higher PTH scores mean a worse outcome.
If there is missing data, LOCF(Last Observation Carried Forward) was applied and analyzed.</description>
        <time_frame>baseline, 6months, 12months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Risendronate/Cholecalciferol Combination</title>
            <description>Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months.
Risedronate/Cholecalciferol combination: once a week</description>
          </group>
          <group group_id="O2">
            <title>Risedronate</title>
            <description>Active comparator: Administer Risendronate one tablet once a week for 12months.
Risedronate: once a week</description>
          </group>
        </group_list>
        <measure>
          <title>PTH(Parathyroid Hormone Value)</title>
          <description>range of PTH: 13~54 Higher PTH scores mean a worse outcome.
If there is missing data, LOCF(Last Observation Carried Forward) was applied and analyzed.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="642"/>
                <count group_id="O2" value="199"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>PTH(baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.48" spread="30.95"/>
                    <measurement group_id="O2" value="39.17" spread="34.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTH(6months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.34" spread="23.82"/>
                    <measurement group_id="O2" value="42.40" spread="27.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTH(12months)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.17" spread="19.37"/>
                    <measurement group_id="O2" value="45.27" spread="23.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTH change(6months-baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.78" spread="23.36"/>
                    <measurement group_id="O2" value="3.39" spread="35.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTH change(12months-baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="27.31"/>
                    <measurement group_id="O2" value="6.16" spread="33.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12months</time_frame>
      <desc>The safety evaluation was conducted in the safety set(Risendronate/Cholecalciferol Combination: 806, Risendronate: 247) Safety set means exclude do not administering investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>Risendronate/Cholecalciferol Combination</title>
          <description>Experimental: Administer Risendronate/Cholecalciferol combination one tablet once a week for 12months.
Risedronate/Cholecalciferol combination: once a week</description>
        </group>
        <group group_id="E2">
          <title>Risedronate</title>
          <description>Active comparator: Administer Risendronate one tablet once a week for 12months.
Risedronate: once a week</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="806"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="806"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Prinzmetal angina</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Distal intestinal obstruction syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastric polyps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rectal prolapse</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Incisional hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Ketoacidosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Still's disease adult onset</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Gallbladder cancer stage IV</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Pyogenic granuloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Thyroid neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Brain oedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Hydrocephalus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Bronchitis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Elderly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="806"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="806"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="21" subjects_affected="20" subjects_at_risk="806"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="806"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="806"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="247"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="806"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="247"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Multiple centers proceded clinical study do not use the same measuring instrument.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Clinical Trial Unit</name_or_title>
      <organization>Hanlim Pharma</organization>
      <phone>82-2-3489-6297</phone>
      <email>yrsong@hanlim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

